Ambalal Sarabhai Enterprises Limited (NSE:AMBALALSA)
India · Delayed Price · Currency is INR 31.99
+1.05 (3.39%)
At close: Jul 21, 2026
NSE:AMBALALSA Revenue
In the fiscal year ending March 31, 2026, Ambalal Sarabhai Enterprises had annual revenue of 2.03B INR with 2.64% growth. Ambalal Sarabhai Enterprises had revenue of 657.50M in the quarter ending March 31, 2026, a decrease of -0.32%.
Revenue
2.03B
Revenue Growth
+2.64%
P/S Ratio
1.19
Revenue / Employee
3.70M
Employees
547
Market Cap
2.41B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 2.03B | 52.02M | 2.64% |
| Mar 31, 2025 | 1.97B | 230.03M | 13.20% |
| Mar 31, 2024 | 1.74B | 32.87M | 1.92% |
| Mar 31, 2023 | 1.71B | -266.02M | -13.46% |
| Mar 31, 2022 | 1.98B | 324.75M | 19.66% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Medico Remedies | 2.06B |
| Ambalal Sarabhai Enterprises | 2.03B |
| Medicamen Biotech | 2.01B |
| Sat Kartar Life | 2.01B |
| Everest Organics | 1.97B |
| Gennex Laboratories | 1.73B |
| Astonea Labs | 1.48B |
| Kerala Ayurveda | 1.31B |
Ambalal Sarabhai Enterprises News
- 4 months ago - EXCLUSIVE: Co-Diagnostics Expands South Asia Reach, Targets $13 Billion Market Opportunity - Benzinga